Nautilus Q2 net loss $14.7M; cash $334.9M; platform launch on track for mid-2024

Nautilus Biotechnology, Inc.

2022-Q2 EPS reported -$0.24

Operating expenses of $15.5M in Q2 2022, down from $16.0M in Q1 2022.
Net loss of $14.7M for Q2 2022 vs. $10.7M in Q2 2021; cash, equivalents & investments $334.9M.
Platform launch (instruments and reagents) targeted for mid-2024; early access revenue starting early 2024.
Anticipates cash runway extending well into 2025.
Hired Eric Spence (VP Instrument Engineering) and Ken Kuhn (VP Reagent & Process Development).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.